I'm reaching out to introduce Novel Bio, a biotech transforming DNA manufacturing with its proprietary NBx Platform—a rapid, high-yield alternative to E. coli. This innovation enables faster, higher-quality, and more affordable plasmid DNA production, removing a key barrier to progress in gene therapy, synthetic biology, and biopharma.
The company generates revenue both as a CDMO delivering DNA on demand for more than 10 clients with a 100% retention rate, and through sales of their NBx CyClone Cell Line to over 25 clients (including the NIH, Regeneron, AstraZeneca and others).
NBx Cyclone offers a drop-in replacement for the current workflows, delivering up to 10x more plasmids with superior DNA quality. In fact, Novel Bio was able to manufacture a specific strain of DNA in two days for the NIH, which was unable to create it in 6 months using current methods. Best of all, it doesn’t require new equipment or retraining for lab staff.
Novel Bio is uniquely positioned to become the new backbone of DNA manufacturing - unlocking faster, more affordable, and more reliable biotech innovation worldwide. With demand currently outpacing capacity, the company is raising capital to expand manufacturing and scale its business.
Please let me know if you're interested in learning more about the investment opportunity with Novel Bio. I would be happy to request a deck and/or arrange a meeting with their team.
Thank you for your time and consideration.